Biora Therapeutics
Biora Therapeutics innovates smart-pill technologies for targeted drug delivery, focusing on improving patient outcomes for chronic and inflammatory diseases.
Company History
Biora Therapeutics was founded in 2010 originally as Ascendant MDx, Inc. In 2013, the company changed its name to Progenity, Inc. and underwent another rebranding in 2022, becoming Biora Therapeutics, Inc. The company went public with its initial public offering on June 19, 2020. In 2021, Biora Therapeutics shifted its strategic focus to the development of an innovative therapeutics pipeline aimed at improving patient outcomes via smart capsule technology.
Therapeutic Technologies
Biora Therapeutics specializes in developing therapeutic technologies designed to improve the delivery and efficacy of drug treatments. The company's flagship tech includes the NaviCap™ Targeted Oral Delivery Platform and the BioJet™ Systemic Oral Delivery Platform. NaviCap™ aims at treating inflammatory bowel disease by delivering drugs directly to the large intestine, while BioJet™ facilitates the systemic uptake of large molecules in the small intestine, offering a needle-free solution for chronic disease management.
NaviCap™ Targeted Oral Delivery Platform
The NaviCap™ Targeted Oral Delivery Platform is designed to deliver therapeutics to the large intestine, specifically targeting the site of disease in patients with inflammatory bowel disease. This platform uses a smart capsule to improve the safety and effectiveness of drug therapies by ensuring precise delivery to affected areas. Device function studies have been conducted in both healthy volunteers and patients with active ulcerative colitis, involving over 70 NaviCap devices in more than 40 study participants.
BioJet™ Systemic Oral Delivery Platform
The BioJet™ Systemic Oral Delivery Platform offers an innovative method for the oral delivery of biotherapeutics, aiming to replace traditional injections. The ingestible capsule delivers a liquid jet of biotherapeutics into the small intestine for systemic uptake. In animal experiments, the BioJet platform has demonstrated an average bioavailability of 20-37% for GLP-1 receptor agonists, significantly higher than the less than 1% bioavailability of current oral tablets. The platform supports a wide range of large molecules, including monoclonal antibodies, peptides, and nucleic acids.
Collaborations
Biora Therapeutics collaborates with leading pharmaceutical companies such as AstraZeneca and Ionis Pharmaceuticals to explore the delivery capabilities of the BioJet platform. These collaborations aim to evaluate and optimize the BioJet platform for the delivery of various therapeutic molecules, potentially expanding the range of treatable chronic conditions through advanced delivery mechanisms.